Clinical trials located in

Ruse

Ruse city is located in Bulgaria. Currently, 20 clinical trials are being conducted in this city.

Ruse, Bulgaria, stands out as a significant Danube River port, often dubbed “Little Vienna” for its neoclassical architecture. Founded by the Romans, it boasts a rich history, including the first Bulgarian newspaper and railway system. The city is home to the Ruse Regional Historical Museum, showcasing Thracian art and artifacts. The Freedom Square is a central hub, surrounded by exquisite 19th-century buildings. Ruse also played a pivotal role in Bulgaria’s liberation from Ottoman rule.

  • CT-EU-00041455

    Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    • Tanimilast/CHF6001
    • Roflumilast
  • Study of new drug ARV-471 (PF-07850327) and fulvestrant in patients with advanced breast cancer

    The study looks at advanced breast cancer that has spread to other parts of the body (metastasizes). It is aimed at patients with ER+/HER2- breast cancer, which means that the cancer responds to estrogen (a hormone) and does not have excessive amounts of the HER2 protein. The study will compare two drugs: ARV-471 (PF-07850327, vepdegestrant) and fulvestrant.

    Fulvestrant is a drug already used to treat breast cancer, while ARV-471 is a new drug. The aim of this study is to determine whether ARV-471 is safe and effective compared to fulvestrant in patients with advanced breast cancer that cannot be cured by surgery or radiotherapy.

    The study is open to adults with breast cancer recurrence or metastases that cannot be fully cured by surgery or radiotherapy. Candidates should have a confirmed diagnosis of ER+/HER2- breast cancer and previous treatment with CDK4/6 inhibitors combined with hormonal therapy. Patients must not have active brain metastases or liver, kidney or bone marrow failure.

    Treatment continues until the cancer gets worse or the side effects become too severe. Clinic meetings take place approximately every 4 weeks.

    • Vepdegrestrant/ARV-471
    • Fulvestrant
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    • Ozanimod
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    • Milvexian
  • Testing the safety and efficacy of Ruxolitinib cream in prurigo nodularis therapy

    This clinical trial is to test a cream with Ruxolitinib on people with a skin condition called prurigo nodularis (PN) over a period of about one year. The trial is divided into three stages. In the first 12 weeks, participants will use either the Ruxolitinib cream or a placebo cream on the skin where PN appears. In the next 40 weeks, the Ruxolitinib cream will only be applied to the areas where PN is active. The last 30 days are to watch for any side effects. The trial will monitor changes in the severity of itching and the number of PN bumps on the skin. Any possible side effects will be recorded too.

    • Ruxolitinib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    • Tanimilast/CHF6001
  • A new drug trial for the treatment of lupus

    This research studies a new drug, ESK-001, for adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The trial will compare ESK-001’s effectiveness and safety against a placebo over 48 weeks. It will involve 388 participants, randomized to receive either ESK-001 or a placebo. The main focus is to see if ESK-001 can reduce lupus symptoms and improve quality of life. Researchers will also monitor any side effects and overall safety of the drug.

    • ESK-001- new potential medication for autoimmune disorders
  • Studying effects of tozorakimab on Chronic Obstructive Pulmonary Disease (COPD)

    This clinical study evaluates the efficacy and safety of Tozorakimab in treating adults with Chronic Obstructive Pulmonary Disease (COPD) who have a history of frequent exacerbations. Participants, who must have experienced at least two moderate or one severe exacerbation in the past year, will receive tozorakimab through subcutaneous injections. The study aims to reduce the rate of COPD exacerbations over a one-year period. Participants will continue their usual inhaled lung therapies alongside the trial treatments.

    • Tozorakimab
  • Investigating a new inhaler’s impact: comparative study in asthma treatment

    The study is designed to assess whether PT010, a new inhaler, can be beneficial for adults and teenagers with poorly managed asthma. PT010 comprises three active ingredients: budesonide, glycopyrronium, and formoterol. The comparative analysis aims to determine the effectiveness and safety of PT010 in comparison to another inhaler containing budesonide and formoterol, as well as the widely used Symbicort inhaler. The study will span from 24 to 52 weeks and involve approximately, 2200 participants from various locations. The primary focus will be on the improvement of lung function within 24 weeks, alongside evaluating the reduction in the frequency of asthma attacks and its impact on quality of life and respiratory control.

    • Symbicort
    • Budesonide/formoterol fumarate (BFF pMDI)
    • budesonide/glycopyrronium/formoterol (BGF MDI)
  • Studying tozorakimab for long-term safety in patients with chronic obstructive pulmonary disease

    The research study focuses on Tozorakimab’s long-term safety and efficacy in adults over 40 with frequent COPD flare-ups. It aims to evaluate the time until the first severe flare-up post-treatment, comparing it with the effects of current COPD treatments. The study also assesses Tozorakimab’s additional benefits alongside standard care and monitors participants’ blood for drug levels and physiological reactions. This research is key in developing improved management strategies for COPD.

    • Tozorakimab
  • Benralizumab trial for Chronic Lung Disease (COPD) patients

    This Phase 3 clinical trial evaluates Benralizumab in treating COPD, a severe lung condition characterized by breathing difficulties. It specifically targets individuals who experience frequent flare-ups, despite ongoing medication. The trial requires participants to have had at least two flare-ups in the previous year and a high eosinophil count in their blood. The study involves administering Benralizumab for a minimum of 56 weeks, with the aim to assess its impact on reducing flare-ups and improving lung function.

    • Benralizumab
  • Tozorakimab study for viral lung infection in hospitalized patients needing oxygen

    This clinical trial evaluates the effectiveness and safety of tozorakimab for hospitalized patients with viral lung infections requiring supplemental oxygen. The study involves two groups: one receiving tozorakimab and the other a placebo, alongside standard care. The main goal is to see if tozorakimab can lower the risk of death or the need for intensive respiratory support. The study involves adult patients and aims to measure various health outcomes, including mortality rates and the length of intensive care and oxygen support.

    • Tozorakimab
  • Assessing the efficacy of atuliflapon in uncontrolled asthma relief

    This study is looking at atuliflapon, a new medication, for adults with moderate to severe uncontrolled asthma. The trial is a Phase 2 study, which means it’s testing how effective and safe atuliflapon is. About 1,102 adults who are already using asthma medications will be part of this study. They will take atuliflapon or a placebo once a day for 12 weeks. The goal is to see if atuliflapon can help reduce asthma attacks and improve breathing in people whose asthma isn’t well-controlled with their current treatments.

    • Atuliflapon
  • Research study on COPD treatment with new drug mitiperstat

    This study is testing a new drug, mitiperstat, for people with moderate to severe chronic obstructive pulmonary disease (COPD). It’s a Phase IIa trial where 288 adults will either get mitiperstat or a placebo. This setup allows researchers to compare the effects of mitiperstat against no treatment to determine if it effectively reduces the severity and frequency of COPD symptoms. The aim is to see if mitiperstat can help reduce COPD symptoms and how safe it is. Participants will take the drug or placebo once a day.

    • Mitiperstat
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine
  • Testing a new drug for skin lupus treatment

    This clinical trial aims to test and gather data on the efficacy of a new drug, BIIB059 (litifilimab), in treating active subacute cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE). The trial is specifically for patients who have unsuccessfully tried, or experienced intolerance to, antimalarial treatments. Along with assessing the reduction in the patient’s skin disease activity, the trial will evaluate safety, tolerability, and immunogenicity of BIIB059. Both SCLE and CCLE patients with or without systemic manifestations can participate. The trial involves blind testing and consists of injecting BIIB059 or a placebo to the participants once every four weeks.

    • Litifilimab
  • Comparison of milvexian and apixaban in reducing stroke risk in patients with atrial fibrillation

    This study is designed to compare two drugs, Milvexian and Apixaban to reduce the potential risk of stroke for patients suffering from atrial fibrillation, a common heart rhythm disorder. 15500 participants, aged 18 years and older will be invited to partake in this research. Participants will be randomly designated to receive either Milvexian or Apixaban. The study team aims to determine if Milvexian is at least as effective as Apixaban in reducing the risk of combined stroke and Non-central nervous system (CNS) systemic embolism. Furthermore, the research team will evaluate the occurrence rates of various health incidents including major bleeding, various cardiovascular complications, death, and other severe conditions over a 4-year period. The goal is to find out which medication proves safer and more effective in preventing severe health risks linked with this disorder. Study commencement is April 11, 2023, with completion targeted at May 5, 2027.

    • Apixaban
    • Milvexian

See more clinical trials in other cities in Bulgaria:

.